Luminespib

Drug Profile

Luminespib

Alternative Names: AUY-922; NVP-AUY-922; VER-52296

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research Technology; The Institute of Cancer Research; Vernalis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis; Royal Marsden NHS Foundation Trust; Sarah Cannon Research Institute; SCRI Development Innovations; The Institute of Cancer Research; University of Texas M. D. Anderson Cancer Center; University of Toronto; Vernalis
  • Class Amides; Antineoplastics; Isoxazoles; Morpholines; Resorcinols; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Head and neck cancer
  • Suspended Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Lymphoma; Multiple myeloma; Myeloproliferative disorders; Non-small cell lung cancer; Solid tumours
  • Discontinued Pancreatic cancer

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 24 Jun 2018 Biomarkers information updated
  • 25 Apr 2017 Preclinical trials in Head and neck cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top